Comments
Loading...

Black Diamond Therapeutic Analyst Ratings

BDTXNASDAQ
Logo brought to you by Benzinga Data
$1.67
0.000.00%
Pre-Market: 4:25 AM EDT
Consensus Rating1
Outperform
Highest Price Target1
$20.00
Lowest Price Target1
$12.00
Consensus Price Target1
$15.60

Black Diamond Therapeutic Analyst Ratings and Price Targets | NASDAQ:BDTX | Benzinga

Black Diamond Therapeutics Inc has a consensus price target of $15.6 based on the ratings of 5 analysts. The high is $20 issued by Raymond James on July 31, 2024. The low is $12 issued by HC Wainwright & Co. on March 18, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Stifel, and HC Wainwright & Co. on March 18, 2025, March 7, 2025, and November 6, 2024, respectively. With an average price target of $12.67 between HC Wainwright & Co., Stifel, and HC Wainwright & Co., there's an implied 658.48% upside for Black Diamond Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Oct 24
1
Nov 24
2
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Stifel
Wedbush
Piper Sandler
Raymond James

1calculated from analyst ratings

Analyst Ratings for Black Diamond Therapeutic

Buy NowGet Alert
03/18/2025Buy Now618.56%HC Wainwright & Co.
Robert Burns42%
$11 → $12MaintainsBuyGet Alert
03/07/2025Buy Now798.2%Stifel
Bradley Canino40%
$16 → $15MaintainsBuyGet Alert
11/06/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$11 → $11ReiteratesBuy → BuyGet Alert
10/09/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$11 → $11ReiteratesBuy → BuyGet Alert
10/08/2024Buy Now858.08%Wedbush
Robert Driscoll44%
$16 → $16ReiteratesOutperform → OutperformGet Alert
09/24/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$11 → $11ReiteratesBuy → BuyGet Alert
09/23/2024Buy Now798.2%Piper Sandler
Joseph Catanzaro42%
$12 → $15MaintainsOverweightGet Alert
09/18/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$11 → $11ReiteratesBuy → BuyGet Alert
09/10/2024Buy Now858.08%Wedbush
Robert Driscoll44%
$16 → $16ReiteratesOutperform → OutperformGet Alert
09/04/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$11 → $11ReiteratesBuy → BuyGet Alert
08/07/2024Buy Now858.08%Wedbush
Robert Driscoll44%
$16 → $16ReiteratesOutperform → OutperformGet Alert
07/31/2024Buy Now1097.6%Raymond James
Laura Prendergast23%
→ $20Initiates → OutperformGet Alert
07/03/2024Buy Now618.56%Piper Sandler
Joseph Catanzaro42%
$12 → $12MaintainsOverweightGet Alert
06/07/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$11 → $11ReiteratesBuy → BuyGet Alert
05/16/2024Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
$12 → $11MaintainsBuyGet Alert
04/08/2024Buy Now858.08%Wedbush
Robert Driscoll44%
$10 → $16MaintainsOutperformGet Alert
03/18/2024Buy Now618.56%HC Wainwright & Co.
Robert Burns42%
$11 → $12ReiteratesBuy → BuyGet Alert
03/13/2024Buy Now498.8%Wedbush
Robert Driscoll44%
$10 → $10ReiteratesOutperform → OutperformGet Alert
11/22/2023Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
→ $11ReiteratesBuy → BuyGet Alert
09/12/2023Buy Now498.8%Wedbush
Robert Driscoll44%
→ $10ReiteratesOutperform → OutperformGet Alert
07/14/2023Buy Now558.68%Piper Sandler
Joseph Catanzaro42%
→ $11Initiates → OverweightGet Alert
06/30/2023Buy Now498.8%Stifel
Bradley Canino40%
$2 → $10UpgradeHold → BuyGet Alert
06/28/2023Buy Now558.68%HC Wainwright & Co.
Robert Burns42%
→ $11UpgradeNeutral → BuyGet Alert
06/27/2023Buy Now19.76%Stifel
Bradley Canino40%
→ $2ReiteratesHold → HoldGet Alert
06/27/2023Buy Now498.8%Wedbush
Robert Driscoll44%
$3 → $10UpgradeNeutral → OutperformGet Alert
05/10/2023Buy Now79.64%Wedbush
Robert Driscoll44%
→ $3Reiterates → NeutralGet Alert
03/29/2022Buy NowWedbush
Robert Driscoll44%
DowngradeOutperform → NeutralGet Alert

FAQ

Q

What is the target price for Black Diamond Therapeutic (BDTX) stock?

A

The latest price target for Black Diamond Therapeutic (NASDAQ:BDTX) was reported by HC Wainwright & Co. on March 18, 2025. The analyst firm set a price target for $12.00 expecting BDTX to rise to within 12 months (a possible 618.56% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?

A

The latest analyst rating for Black Diamond Therapeutic (NASDAQ:BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic maintained their buy rating.

Q

When was the last upgrade for Black Diamond Therapeutic (BDTX)?

A

The last upgrade for Black Diamond Therapeutics Inc happened on June 30, 2023 when Stifel raised their price target to $10. Stifel previously had a hold for Black Diamond Therapeutics Inc.

Q

When was the last downgrade for Black Diamond Therapeutic (BDTX)?

A

The last downgrade for Black Diamond Therapeutics Inc happened on March 29, 2022 when Wedbush changed their price target from N/A to N/A for Black Diamond Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.

Q

Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?

A

While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a maintained with a price target of $11.00 to $12.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $1.67, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch